Proteostasis Therapeutics, Inc.
200 Technology Square
Suite 402
Cambridge
Massachusetts
02139
United States
Website: http://www.proteostasis.com/
Email: info@proteostasis.com
117 articles about Proteostasis Therapeutics, Inc.
-
In addition to massive layoffs – around 60% of its workforce – Yumanity also said it is considering “strategic alternatives” to its financial woes, including the possibility of selling or merging.
-
Yumanity Therapeutics Completes Reverse Merger with Proteostasis Therapeutics
12/23/2020
Shares of Yumanity to commence trading on Nasdaq under new ticker symbol “YMTX” on December 23, 2020 $33.6 million common stock private investment in public equity (“PIPE”) transaction closes concurrently with the merger
-
Proteostasis Therapeutics, Inc. Stockholders Approve Business Combination with Yumanity Therapeutics, Inc.; Board Sets Reverse Stock Split Ratio
12/22/2020
Proteostasis Therapeutics, Inc. ("Proteostasis") (Nasdaq: PTI) announced today that, based on the final vote count certified by the inspector of elections at its reconvened special meeting of stockholders held at 9:00 a.m. Eastern Time on December 22, 2020 (the "Special Meeting"), its stockholders approved all of the proposals related
-
Proteostasis Therapeutics Reports Third Quarter 2020 Financial Results
11/16/2020
- Proteostasis Therapeutics, Inc. (Nasdaq:PTI), a clinical stage biopharmaceutical company, today announced financial results for the third quarter ended September 30, 2020 . In August 2020 , Proteostasis and Yumanity Therapeutics, Inc. ("Yumanity"), announced the two companies had entered into a definitive merger agreement. If the me
-
Yumanity Therapeutics and Proteostasis Therapeutics Announce Merger Agreement
8/24/2020
Focus on Yumanity's lead clinical program in Parkinson's disease and transformative pipeline of disease-modifying treatments for neurogenerative disorders
-
They will operate after the deal as Yumanity Therapeutics, and will focus on protein misfolding and neurodegenerative diseases.
-
Proteostasis Therapeutics Reports Second Quarter 2020 Financial Results
8/6/2020
Proteostasis Therapeutics, Inc., a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic fibrosis, announced financial results for the second quarter ended June 30, 2020.
-
Proteostasis Therapeutics Announces Change to Virtual Format for 2020 Annual Meeting of Stockholders
6/5/2020
Proteostasis Therapeutics, Inc. (NASDAQ: PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic fibrosis (CF), today announced that, due to public health and safety concerns related to the ongoing COVID-19 global pandemic and to support the health and well-bei
-
Proteostasis Therapeutics Announces In Vitro Data for PTI-129 as Potential Treatment Candidate for COVID-19
6/1/2020
Proteostasis Therapeutics, Inc. (Nasdaq:PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic fibrosis (CF), today announced results from in vitro studies evaluating the use of PTI-1
-
Proteostasis Therapeutics Reports First Quarter 2020 Financial Results and Provides Corporate Update
5/15/2020
Proteostasis Therapeutics, Inc. (Nasdaq: PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic fibrosis (CF), today announced financial results for the first quarter ended March 31, 2020 and provided a corporate update.
-
Proteostasis Therapeutics to Present at the 2020 RBC Capital Markets Global Healthcare Virtual Conference
5/13/2020
Proteostasis Therapeutics, Inc. (NASDAQ:PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic fibrosis (CF), today announced that Proteostasis management will present at the 2020 RBC Capital Markets Global Healthcare Virtual Conference on Wednesday, May 20, 2020
-
Proteostasis Therapeutics Announces Completion of Scientific Advice Meeting with the Dutch Medicines Evaluation Board
4/13/2020
Dutch Regulatory Board Supportive of CHOICES Program, Which May Lead Toward Market Authorization for Treatment of People Living with CF
-
Proteostasis Therapeutics Reports Fourth Quarter and Year-End 2019 Financial Results and Provides Corporate Update
3/10/2020
Proteostasis Therapeutics, Inc. (Nasdaq: PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic fibrosis (CF) through theratyping, today announced financial results for the fourth quarter and full year ended December 31, 2019 , and provided a corporate update.
-
Proteostasis Therapeutics Announces New Publication on the Mechanism of Action of a Novel Class of CFTR Modulators Called Amplifiers in the Journal of Cystic Fibrosis
2/25/2020
Proteostasis Therapeutics, Inc. (NASDAQ: PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic fibrosis (CF), today announced the publication of nonclinical data on the mechanism of action of nesolicaftor (PTI-428).
-
Proteostasis Therapeutics and CF Europe Announce Completion of Patient Enrollment for CHOICES, the First-Ever Personalized Medicine-Based Study in Cystic Fibrosis
2/24/2020
Proteostasis Therapeutics, Inc. (NASDAQ:PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic fibrosis (CF) and CF Europe, the federation of 48 national CF Associations in Europe, today announced the completion of enrollment of 502 patients with CF for HIT-CF, a European-based initiative that is paving the path to personalized medicine through the CHOICES clinical trial.
-
Proteostasis Therapeutics Announces Keystone Symposia Presentation of Organoid Study from More than 300 Adult CF Patients
1/22/2020
Proteostasis Therapeutics, Inc. (NASDAQ:PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic fibrosis (CF) and other diseases caused by dysfunctional protein processing, today announced the presentation of results from an ex vivo study of the Company's proprietary cystic fibrosis transmembrane conductance regulato
-
Proteostasis Therapeutics Regulatory Update Following Scientific Advice Meeting with MHRA
1/13/2020
Proteostasis Therapeutics, Inc. (NASDAQ:PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic fibrosis (CF), today announced a regulatory update following the completion of a scientific advice meeting with the Medicines and Healthcare Products Regulatory Agency (MHRA), UK, regarding its two pivotal studies, MORE and CHOICES.
-
Clinical Catch-Up: December 16-20
12/23/2019
Heading into the holidays, there was still plenty of clinical trial news last week. Here’s a look. -
Proteostasis Therapeutics Announces Positive Phase 2 Topline Results from Proprietary CFTR Modulator Combinations in F508del Homozygous Cystic Fibrosis Patients
12/17/2019
Proteostasis Therapeutics, Inc. (NASDAQ: PTI), today announced positive topline results from the Company's global, multicenter, randomized, placebo-controlled, 28-day, Phase 2 study evaluating its proprietary cystic fibrosis transmembrane conductance regulator (CFTR) modulator combinations in F508del homozygous and heterozygous CF subjects 18 years of age and older
-
Proteostasis Therapeutics to Initiate First Ever Personalized Medicine-Based Clinical Trial, CHOICES, in European CF Patients with Genotypes Ineligible for Approved CFTR Modulators
12/11/2019
Proteostasis Therapeutics, Inc. (NASDAQ: PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic fibrosis (CF), today announced positive, initial ex-vivo results of PTI's proprietary cystic fibrosis transmembrane conductance regulator (CFTR) modulators, PTI-801, PTI-808, and PTI-428,